AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04745572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Carbohydrate Diet
Description: Participants randomized to this group will participate in a group-based weight behavioral management program and consume a high carbohydrate (HC) diet. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine HC diet with time-restricted eating (TRE) or HC diet with additional exercise counseling and support.
Study NCT04745572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced Carbohydrate Diet
Description: Participants randomized to this group will participate in a group-based behavioral weight management program and consume a reduced carbohydrate (RC) diet. Because this is a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine RC diet with time-restricted eating (TRE) or RC diet with additional exercise counseling and support.
Study NCT05947981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 5%, normal saline
Description: Decrease fasting hours
Study NCT05947981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose 5%, normal saline
Description: Decrease fasting hours
Study NCT06506526 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hypochlorite irrigating solution
Description: 2 ml 1% NaOCl after each file
Study NCT06506526 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: one minute NaOCL+Chitosan
Description: 2 ml 1% NaOCl after each file then with 5 ml of 0.2% chitosan for one minute.
Study NCT06506526 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Three minute NaOCL+Chitosan
Description: 2 ml 1% NaOCl after each file then with 5 ml of 0.2% chitosan for three minute.
Study NCT04369040 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: High-flow nasal oxygen therapy using a specific nasal cannula
Description: Patient in this arm will received high-flow nasal oxygen therapy ventilation during the ENT surgery
Study NCT04369040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow Controlled Ventilation using a laryngeal tri-tube
Description: Patient in this arm will received a laryngeal tri-tube ventilation during the ENT surgery
Study NCT05499052 — intervention group
Intervention type: DRUG
Intervention: REKOVELLE®
Description: Subjects must be treated according to the routine clinical practice and REKOVELLE® must be prescribed in accordance with the terms of the marketing authorisation of each participating country.~According to the label the REKOVELLE® dose should be based on a recent determination of body weight and a recent determination of Anti-Müllerian Hormone (AMH) (i.e. within the last 12 months) measured by the following diagnostic tests: ELECSYS AMH Plus immunoassay from Roche or alternatively the ACCESS AMH Advanced from Beckman Coulter or LUMIPULSE G AMH from Fujirebio.
Study NCT05002738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel and Ethinyl Estradiol Tablets
Description: Combined oral contraceptive pill
Study NCT06519201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SRT with SpineCare
Description: Korean medicine doctors performed the treatment regimens.The TG underwent SRT with SpineCare. Treat-ment was administered for six consecutive weeks, with sessions held twice per week dur-ing the first four weeks and once per week during the final two weeks. No additional treatments (e.g., procedures or surgeries) were allowed during the six-week period. To an-alyze pain according to the number of treatment sessions, a counselor assessed patients using the NRS after each of the ten treatment sessions. To compare the differences in Cobb's angle between the groups, X-rays were performed after the first and tenth treatment sessions. Detailed records of adverse events were maintained before and after each treat-ment session.
Study NCT06519201 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SRT without SpineCare
Description: Korean medicine doctors performed the treatment regimens. The CG underwent SRT without SpineCare. Treat-ment was administered for six consecutive weeks, with sessions held twice per week dur-ing the first four weeks and once per week during the final two weeks. No additional treatments (e.g., procedures or surgeries) were allowed during the six-week period. To an-alyze pain according to the number of treatment sessions, a counselor assessed patients using the NRS after each of the ten treatment sessions. To compare the differences in Cobb's angle between the groups, X-rays were performed after the first and tenth treatment sessions. Detailed records of adverse events were maintained before and after each treat-ment session.
Study NCT05136482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryocompression
Description: A cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will exert a constant pressure of 25 mmHg throughout each test session. The device will pump temperature-controlled cold water through the cuff in order to reduce the skin temperature around the knee (and intra-articular temperature). Depending on the condition, the temperature of the water being pumped through the device will be either 6, 8, 10, or 12℃. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature >15℃.
Study NCT05406466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: a PD-1 immune check inhibitor
Study NCT05406466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: multitargeted receptor tyrosine kinase inhibitor
Study NCT05406466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
Study NCT05790252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Transdermal Matrix Patch
Description: Buprenorphine transdermal patches will be applied at time of induction initiation and removed at 48 hours.
Study NCT05790252 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham patch
Description: Bandage applied at time of induction initiation and removed at 48 hours.
Study NCT06452914 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Socks
Description: Socks not containing the Semiconductor Embedded Therapeutic fabric
Study NCT04467502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive-behavioral therapy for gambling disorder
Description: 6 sessions of cognitive-behavioral therapy for gambling disorder
Study NCT04467502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: imaginal exposure therapy focus on gambling cues
Description: 6 sessions of imaginal exposure therapy focus on gambling cues
Study NCT04467502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality exposure therapy focus on gambling cues
Description: 6 sessions of virtual reality exposure therapy focus on gambling cues
Study NCT06536478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: 50 minutes of exercise twice a week, including stretching, core exercises, gross motor movements and balance exercises for 5 weeks
Study NCT06536478 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: education
Description: The patient will be given a one-time exercise education session and a 50-minute video that included stretching, core exercises, gross motor movements and balance exercises that could be practiced at home.
Study NCT06052293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANG003
Description: To evaluate four possible combinations of lipase, protease and amylase.
Study NCT04621604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Description: Extra blood samples will be collected during chemotherapy administration to analyze pharmacokinetics of the iPD1
Study NCT06185140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiac rehabilitation program
Description: Cardiac rehabilitation program
Study NCT06185140 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TELEA platform
Description: TELEA platform
Study NCT04679116 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic bilateral inguinal hernia repair
Description: Laparoscopic bilateral inguinal hernia repair
Study NCT04679116 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open bilateral inguinal hernia repair
Description: Open bilateral inguinal hernia repair
Study NCT04924465 — intervention group
Intervention type: OTHER
Intervention: Follow-up
Description: Follow-up of clinical data, laboratory tests, radiological data and pulmonary function tests
Study NCT05991401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8010 5mg
Description: \[Period 1\] DA-8010 5mg \[Period 2\] DA-8010 5mg, Clarithromycin 500mg \[Period 3\] DA-8010 5mg, Rifampicin 600mg
Study NCT05991401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Description: \[Period 2\] DA-8010 5mg, Clarithromycin 500mg
Study NCT05991401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin 600mg
Description: \[Period 3\] DA-8010 5mg, Rifampicin 600mg
Study NCT05987696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD33/CLL1 dual CAR-NK cell
Description: NK cell therapy
Study NCT05987696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: Lympho-conditioning Agent
Study NCT04937049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMAeHealth digital tool
Description: eHealth intervention to support Maternal Education
Study NCT06337903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-compassion intervention (the Mindful Self-Compassion course)
Description: An online 8-week mindful self-compassion course with weekly sessions.
Study NCT04888507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab
Description: Intravenous (IV) loading dose (once) followed after 30 minutes by sub-cutaneous (SC) administration
Study NCT04888507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: SC administration
Study NCT05956782 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathe Easier
Description: See Intervention Group (IG) description.
Study NCT05956782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathe Easier
Description: See Intervention Group (IG) description.
Study NCT04943627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab (BAL)
Description: Anti-PD-1 Monoclonal antibody
Study NCT04943627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Chemotherapy
Study NCT04943627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Chemotherapy
Study NCT04943627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Chemotherapy
Study NCT04943627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Chemotherapy
Study NCT04943627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Chemotherapy
Study NCT05987696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning Agent
Study NCT05987696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Lympho-conditioning Agent
Study NCT05987696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD33 CAR-NK cell
Description: NK cell therapy
Study NCT05987696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: super NK cell
Description: NK cell therapy
Study NCT06484816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGRX-1942
Description: At dose escalation phase, TGRX-1942 will be given orally to patient once a day under a 7-dose sequence of 4mg, 10mg, 20mg, 30mg, 40mg, 50mg, and 60mg. The dose level a particular patient will be assigned depends on the progression of the study and PI evaluation on the safety of previous dose group(s).
Study NCT05241574 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy boost
Description: Additional endorectal high rate irydium brachytherapy boost, 2 fractions of 10 Gy each.
Study NCT05241574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Additional consolidation chemotherapy
Description: Three additional cycles of 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX4) consolidation chemotherapy
Study NCT05769465 — intervention group
Intervention type: DRUG
Intervention: disease modifying treatments
Description: Patients will be enrolled if exposed to nusinersen, risdiplam, onasemnogene abeparvovec
Study NCT04804579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fall Prevention Intervention
Description: The intervention will aim to reduce fall risk through weekly virtual group meetings and at-home exercise assignments to address physical and environmental factors that may put participants at a higher risk of experiencing a fall.
Study NCT05128578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liver Education About Pain (LEAP)
Description: LEAP is a modular 12-week pain self-management intervention with 6 individual sessions and 6 optional group sessions. Individual sessions serve the purpose of individualizing the program to the needs of the patients. Group sessions allow participants to practice skills, set goals with the group, seek social support, and learn together. The purpose of the LEAP program is to make pain better, help patients reach their personal goals (things that may be hard to do because of pain), and add to the care patients' medical team is providing.
Study NCT05128578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Patients can continue to use other pain management strategies (usual care) in order to mimic real-life conditions.
Study NCT06466369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: tadalafil 2.5 mg, 5 mg
Study NCT06472245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSE2101
Description: OSE2101 is a peptidic cancer vaccine composed of nine epitopes restricted to HLA-A2 phenotype targeting the tumor associated antigens of P53, HER-2, CEA, MAGE-2 and MAGE-3, and one pan-HLA DR binding epitope (PADRE), all epitopes emulsified in Montanide ISA 51TM adjuvant.
Study NCT06472245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions.
Study NCT06472245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NGS HLAA2 assay
Description: Amp-HLA-A-CDx Tedopi for amplification of human genomic DNA (gDNA), LFK-CDx Tedopi kit (library full kit) for library preparation, NGSengine-CDx Tedopi software for analysis of NGS data files.
Study NCT06472245 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NGS HLAA2 assay
Description: Amp-HLA-A-CDx Tedopi for amplification of human genomic DNA (gDNA), LFK-CDx Tedopi kit (library full kit) for library preparation, NGSengine-CDx Tedopi software for analysis of NGS data files.
Study NCT06472245 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NGS HLAA2 assay
Description: Amp-HLA-A-CDx Tedopi for amplification of human genomic DNA (gDNA), LFK-CDx Tedopi kit (library full kit) for library preparation, NGSengine-CDx Tedopi software for analysis of NGS data files.
Study NCT05111548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS (Active)
Description: tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function. Participants in the experimental arm will receive a steady current delivery through the device.
Study NCT05111548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BrainHQ
Description: BrainHQ is a web-based, commercially available cognitive training program that includes exercises to enhance working memory
Study NCT05111548 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: BrainHQ
Description: BrainHQ is a web-based, commercially available cognitive training program that includes exercises to enhance working memory
Study NCT05397080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU + multicomponent treatment VIRTUAL FIBROWALK
Description: Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (15 min.)~* Cognitive restructuring (15 min.)~* Mindfulness techniques (15 min.)~* Physical exercise(15 min.)~* Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia.
Study NCT05397080 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.
Study NCT05397080 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU + multicomponent treatment VIRTUAL FIBROWALK + 4 face-to-face sessions
Description: Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (15 min.)~* Cognitive restructuring (15 min.)~* Mindfulness techniques (15 min.)~* Physical exercise(15 min.)~* Treatment as Usual (TAU)~* 4 face-to-face sessions (1 per mounth) Standard pharmacological treatment usually provided to patients with fibromyalgia.
Study NCT06430164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Training
Description: Gait training: One or multiple short bouts of stepping practice on a treadmill at self-selected or fast speeds will be delivered without FES.
Study NCT06430164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES)
Description: Electrical stimulation involving the parameters and settings proposed here is commonly used in clinical practice and research for pain relief and other applications also referred to as neuromuscular or transcutaneous electrical nerve stimulation. The FES will be delivered using the UDel Stimulator, a custom-designed FES system from the University of Delaware FES lab.~Researchers will use a customized, real-time system to control the stimulator and deliver stimulation during appropriate phases of the gait cycle. Stimulation will be delivered to the ankle dorsiflexors when the subject's foot is in the air (swing phase). Stimulation will be delivered to the ankle plantarflexors during the terminal stance phase of gait. 30-Hz variable frequency stimulation trains will be delivered during gait.
Study NCT06430164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral electrical stimulation paired with cortical magnetic stimulation pulses
Description: The paired associative stimulation (PAS) will be conducted in a static posture (seated or standing), to evaluate effects on somatosensory, spinal-reflex, and/or corticospinal neurophysiology delivered with different stimulation parameters. One or multiple short bouts of stepping practice on a treadmill at self-selected or fast speeds may be completed before and/or after PAS to evaluate gait performance
Study NCT05111548 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS (Inactive)
Description: tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function. Participants in the sham arm will wear the device but will not receive a steady current delivery.
Study NCT06036485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kerecis Omega 3
Description: Decellularized intact fish skin developed for the management of chronic wounds
Study NCT06036485 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical debridement
Description: Superficial sharp surgical debridement technique
Study NCT05813457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRESTO Early Identification Program
Description: The program combines :~1. A population-based information component (information campaign aimed at the general population).~2. A training component for the LPAs (Front Line Actors: general practitioners, school and university medicine, pharmacists, teenagers school and university medicine, pharmacists, teenagers' homes, association networks, SAMU, firemen, etc.).~3. Facilitated access to care for FPE patients in the form of a pivot mobile team that can directly meet the patient at the request of the LPA, initiate care and ensure the relay within a the relay within 4 weeks to the existing specialized psychiatric structures on the site (CMP, CATTP (CMP, CATTP, day hospital, hospitalization unit, child and adolescent psychiatry services) adolescent psychiatry services)